Rapport Therapeutics, Inc. (NASDAQ: RAPP)

Rapport Therapeutics, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule precision medicines for neurological and psychiatric disorders.

Rapport Therapeutics, Inc. has not yet generated product revenue and relies on funding from its founding investors Third Rock Ventures and Johnson & Johnson Innovation JJDC to support its research and development activities.

Rapport Therapeutics, Inc. occupies a niche in the biotechnology sector as a developer of precision medicines that target specific neuronal receptor complexes to improve therapeutic index. Its lead candidate RAP 219 is a negative allosteric modulator of the AMPA receptor that seeks to achieve neuroanatomical selectivity by engaging the TARP gamma 8 protein which is enriched in seizure onset zones. Compared with existing anti seizure medications such as perampanel cenobamate and brivaracetam RAP 219 is designed to reduce exposure in regions linked to side effects thereby offering a differentiated safety profile. The company also faces competition from early stage programs including XEN1101 BHV 7000 PRAX 628 ES 481 and SPN 817 in focal onset seizures and from agents like lithium lamotrigine selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors in bipolar disorder. Its competitive advantages stem from its RAP technology platform which enables the discovery of molecules with regionally restricted activity potentially lower drug drug interaction risk and improved tolerability.

The company serves patients with neurological and psychiatric disorders including those with focal onset seizures primary generalized tonic clonic seizures bipolar mania chronic pain migraine and hearing or vestibular conditions as well as healthcare providers who may prescribe its investigational therapies once approved.